Previously inadequate care home in Carlton now rated good
6 minutes ago
Share
Save
Dan Hunt
BBC News, Nottingham
Share
Save
The care home was rated good after an inspection in March
A care home in Carlton previously assessed as inadequate has been rated good in its latest inspection.
The Care Quality Commission (CQC) found Charnwood Care Home, in Nottinghamshire, had made "significant progress" since it was last inspected in November and gave the home a good rating following an inspection in March.
The care home provides nursing and personal care to older and younger adults as well as people living with both health and dementia-related conditions.
A spokesperson for Charnwood Care Home said they were "delighted" the CQC had recognised the "huge amount" of work undertaken since the last inspection.
According to the CQC, the inspection was carried out as a follow-up after the watchdog previously found incidents of physical harm to residents and inadequate measures to deal with hot weather at the care home.
However, the most recent inspection found the care home, run by Divine Rock Care, is no longer in breach of regulations related to safe care and treatment, safeguarding, consent as well as management and oversight.
'Kind and caring'
The care home says since the previous inspection, it has recruited a new home manager, deputy manager and clinical lead.
The spokesperson for the care home added: "It's exceptionally difficult to move up two ratings at once – having done so speaks volumes about how much we have transformed the home."
According to the inspector's report, staff were "kind and caring" and treated people with "dignity and respect".
Greg Rielly, CQC deputy director of operations in the Midlands, said staff at the care home should be "proud" of the "wide range of improvements" carried out since the last inspection.
Mr Rielly added: "At this inspection, we were pleased to find that Charnwood Care Home had taken on board our feedback from the previous inspection and used this to make improvements to deliver a much better service for residents.
"Leaders had a better oversight and understanding of the service, which meant staff were able to provide more person-centred and safer care."
Follow BBC Nottingham on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@bbc.co.uk or via WhatsApp on 0808 100 2210.
Care home rated inadequate over safety concerns
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
12 minutes ago
- The Sun
New treatment for devastating cancer that DOUBLES survival rate to be rolled out on NHS
THOUSANDS of Brits with bladder cancer could survive for twice as long after a new treatment is given the green light to be dished out on the NHS. Health chiefs have said the approval marks "one of the most hopeful advances in decades for people with bladder cancer". They said there had been real 'unmet need' for patients with the advanced form of the disease. With bladder cancer, up to 29 per cent of people are diagnosed at stage 4, when it has already spread, and only survive for around a year after diagnosis. The treatment is a combination of enfortumab vedotin, an antibody drug made by Astellas and Pfizer, and pembrolizumab, made by Merck. It was approved for use by the National Institute for Health and Care Excellence (Nice) yesterday, which means it can now be used on the NHS for people with bladder cancer. The combination, when tested in clinical trials, gave patients and average of 33.8 months compared with 15.9 months while having chemotherapy. Scientists have also measured the amount of time people that survived without their disease getting worse. They found that those on the treatment had a progression-free survival time of a year compared with six months for those receiving standard treatment. Three in ten patients had no evidence of cancer remaining after the treatment, compared with 14.5 per cent of patients receiving standard care. Martyn Hewett, 75, from Stratford, East London, received the new treatment at Barts Health NHS Trust, after surgery to remove his tumours failed. He said: "I feel very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. The signs and symptoms of cancer "Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said 'most people in your position live for a year', and now, three-and-a-half years later, here I am. "I am going to have an extra few years to see my grandson grow up and maybe even be around to see him get married." The treatment is given via an IV infusion to those whose cancer has spread around their body and cannot be surgically removed. The first drug, enfortumab vedotin, directly targets the cancer cells and kills them, while pembrolizumab helps the immune system to recognise and fight any remaining cancer cells. As well as experiencing better survival rates, patients also have fewer harmful side-effects. About 10,500 people in the UK are diagnosed with bladder cancer each year. The new treatment should help about 1,250 patients annually. Helen Knight, director of medicines evaluation at Nice, said: "This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives." 3 3 Professor Peter Johnson, NHS England's national clinical director for cancer, said: "This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival. "Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks and our rollout to NHS patients will make a huge difference to the lives of those affected and their families." Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: "This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available."
The Sun
12 minutes ago
- The Sun
Stockpiling £700 of fat jabs has got me in debt but I can't bear to weigh 22st again… why price hike makes me sick
MOUNJARO'S upcoming price hike has sent users into a spiral, but one woman who used to weigh 22st while bingeing on pizza and curry can sleep easy knowing she has a £2,000 supply stashed away. Paige Ospray maxed out her credit card and used buy-now-pay-later provider Klarna to get her fill, but with many of the 1.5million Brit users now hoarding fat jab drug s, there could be serious repercussions for people who need it to manage their type 2 diabetes. 4 4 It comes after a huge price rise, which almost doubles the cost of the jabs, was announced last week. This follows Donald Trump 's call for US pharmaceutical companies to address price inconsistencies compared with European markets as he slammed 'freeloaders' relying on Americans to pay more for medicines. As a frantic scramble for the drug gets under way, Paige, 30, reveals why she is hoarding as much as possible before the price rise hits in September, in a move that could create a shortage for others. Admin worker Paige lives with partner, sports coach Ads Jenson, 38, in Birmingham, West Midlands. She says: Signing up to a second online chemist last Friday, I could barely catch my breath as I frantically typed in ' Mounjaro '. Stress pulsated through my body as I clicked 'buy again'. When I saw the price was the same as last month - £160 - I burst into joyful tears. I was buying 7.5mg and had been panicking that it was going to cost two or even three times as much after learning overnight the price had suddenly gone up. Online weight loss forums exploded with panicked users fretting they wouldn't be able to afford it. Some people said they were heartbroken. I understood how they felt. I've been on the weight loss drug since June, having battled the bulge for most of my life. At my heaviest aged 18 I weighed 22st and wore size 24 clothes. Undercover at a black market 'skinny jab party' Hamburgers, chips and pizza, Chinese and creamy Indian curries and sugary soda were my go-to meals. I was a yo-yo dieter trying everything from the milkshake or soup diets, food replacement meals, keto and Atkins. I'd lose a few pounds and reward myself with takeaway and cake. I underwent a failed gastric bypass in June 2018 but developed a hernia and 'weight recidivism', which is where you regain weight after surgery. I plateaued at 16 stone. I needed a different plan so weight loss jabs were a Godsend for me. Stockpiling health risks Professor Claire Anderson, Royal Pharmaceutical Society President, says: 'Weight loss medicines should only ever be used exactly as prescribed, with medical supervision. 'We strongly advise against stockpiling as it can create unnecessary pressure on supply and may prevent others getting the treatment they need. 'It's unsafe to attempt to alter or divide doses by using pens of a different strength than prescribed. Taking these medicines in a way that has not been recommended by a healthcare professional can put your health at risk. 'Anyone worried about the cost or availability of these medicines should speak to their pharmacist or prescriber for advice on safe alternatives. 'We strongly discourage people from trying to source medicines from unregulated suppliers, as they may provide fake or harmful products which are unsafe and carry serious health risks.' Initially I was prescribed Ozempic privately but I switched to Mounjaro as it was rumoured to be more effective. The initial dose in January cost £130 and even then I'd struggle to put aside enough cash to buy the jab. But I went down to 9st 4lbs and a size 8 in five months. The ' food noise ' I'd suffered from all my life vanished. I was able to go to the gym and buy nice clothes. I was no longer the 'fat friend'. I intended to stay on it for life… I need to. But like more than a million other UK users, my world came crashing down on Friday when price hikes were announced overnight. Mounjaro mayhem and a race to borrow cash and stockpile ensured. I had already stretched myself to afford what I am on at the moment, but some months slipped £550 into debt because I wasn't working overtime. But even so I knew I had to buy more before the cost spiralled. My partner Ads supported me, knowing how much it meant to me. For me stockpiling a supply before the price almost doubles is the difference between staying slim or piling on the pounds. 4 4 'These are not cosmetic treatments' Andy Morling, MHRA Deputy Director of Criminal Enforcement, says: 'We see people offering weight loss medicines for sale as a quick fix, without a healthcare professional's prescription, from beauty salons, websites and on social media. "These are not cosmetic treatments; they are powerful medicines that can only be legally and safely dispensed against a prescription issued by a healthcare professional.' Although I look thin, if I stop taking it for even a week, the food thoughts come back and the weight creeps on. I don't overdose on it, I take it sensibly but I am not naturally light-boned. So last weekend I spent £700 on my credit card, Klarna and borrowed from Ads, to finish building a Mounjaro supply before the hikes hit in September. Most people have two pharmacies prescribing privately. Some months my supplier didn't have the medication, so I used an alternative provider. I opened accounts with a number of online prescribers, filled in a quick form and even had the option to inform my GP or not. Some didn't even request proper ID. It's not illegal, because of Britain's strict patient confidentiality laws under the Data Protection Act and UK GDPR. The online pharmacy can only see my health history if I give consent and then I get to choose what parts they can access. By then I'll have seven pens worth around £2,000 which I will use sparingly and should last me seven months. After that I don't know what I will do. I have two choices. Stop the jab and get fat. Or stay slim and face financial ruin I have two choices. Stop the jab and get fat. Or stay slim and face financial ruin. It's lose-lose. The wealthy stay skinny. The rest of us face bailiffs, bulges or the black market. I don't want to go down that route but I understand why people have been freaking out, saying they are 'heartbroken' on online forums and eking out the last of their pens. More than ever people are talking about buying illegally. Of course that isn't safe - you don't really know what you're getting. I have my main online pharmacy and a backup one. But I know other users who have signed up to even more. I've already been juggling bills and falling behind on gas and electricity just to be on Mounjaro. I can't afford to stockpile. But it's essential now - it's obesity discrimination and it makes me sick. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.
BBC News
12 minutes ago
- BBC News
Closed care home Orchard House in Harwell up for sale
A building that was used as a care home that was put into special measures after inspectors found major failings is up for sale for £800, House in Harwell, Oxfordshire, was given a rating of inadequate by the Care Quality Commission (CQC) in 2023 after being told it was outstanding four years was a neurological rehabilitation centre helping up to 10 people dealing with brain and spinal injuries, strokes, minimally conscious states and other conditions two years Active Care Group, which ran Orchard House and said it was "very disappointed" with the rating in 2023, was approached to comment. It is unclear when the home was closed but the CQC said after its last inspection that Orchard House experienced a "steep decline" in residents could not access pain relief medication at certain times because staff were not trained and care plans were "unfinished" and "contained incorrect information".At the time, the Active Care Group said it took "immediate action to ensure staff had the guidance and information to support the residents at the facility".In an online advert, the property is said to contain 11 bedrooms, a meeting room, two kitchens and a therapy in High Street, it also has an office, laundry facilities, a basement and utility provisions. There are also three parking spaces and a landscaped courtyard, JEM Property said. You can follow BBC Oxfordshire on Facebook, X (Twitter), or Instagram.
